Antiemetics for Oncology (NK1 RA, 5HT3 RA, combination)
Customize your policy alerts
Sign up for all Aloha Care policy alerts
Know when Aloha Care releases new policies or updates existing guidance.
Monitor payer policy activity
Policy governing prior authorization, step therapy, and coverage criteria for antiemetic drugs used to prevent or treat chemotherapy-induced nausea and vomiting for Aloha Care members (Medicare and Medicaid specified in places). Affects providers requesting outpatient antiemetic drugs including injectable and oral NK1 RAs, 5HT3 RAs, and combination products.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.